Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:438-444

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by He, Z.-X.
Right arrow Articles by Verani, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by He, Z.-X.
Right arrow Articles by Verani, M. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Blood Pressure Medicines
Hazardous Substances DB
*THALLIUM, ELEMENTAL
*THALLOUS CHLORIDE
Related Collections
Right arrow Cardiovascular imaging agents/Techniques
Right arrow Imaging
Right arrow Nuclear cardiology and PET

(Circulation. 2000;102:438.)
© 2000 American Heart Association, Inc.


Basic Science Reports

Myocardial Blood Flow and Myocardial Uptake of 201Tl and 99mTc-Sestamibi During Coronary Vasodilation Induced by CGS-21680, a Selective Adenosine A2A Receptor Agonist

Zuo-Xiang He, MD; Eduardo Cwajg, MD; Wayne Hwang, MD; Craig J. Hartley, PhD; Etai Funk, BS; Lloyd H. Michael, PhD; Mario S. Verani, MD

From the Section of Cardiology, Baylor College of Medicine/Methodist Hospital, Houston, Tex. Dr He’s current address is Fu Wai Hospital, Dept of Nuclear Medicine, Beijing, China.

Correspondence to Mario S. Verani, MD, Professor of Medicine, Baylor College of Medicine, 6550 Fannin, SM 677, Houston, TX 77030. E-mail mverani{at}bcm.tmc.edu

Background—We investigated the hemodynamic and coronary vasodilatory effects of CGS-21680, a potent selective adenosine A2A agonist, as well as its potential use as a new stress modality in combination with perfusion scintigraphy.

Methods and Results—A stenosis of the left anterior descending coronary artery (LAD) was produced in dogs to reduce the reactive hyperemic response to <20%. Adenosine and CGS-21680 were then separately infused to maximize left circumflex coronary artery (LCx) flow velocity. 201Tl (0.5 mCi) and 99mTc-sestamibi (5 mCi) were injected at the maximal dose of CGS-21680. Heart rate decreased with adenosine but increased during CGS-21680 infusion (P<0.005). The decrease in systolic blood pressure was more prominent with adenosine than with CGS-21680 (P<0.005). In the control LCx zone, maximal myocardial blood flow (MBF) (measured by radioactive microspheres) increased 3.1-fold during adenosine infusion (P<0.005) and 3.8-fold during CGS-21680 infusion (P<0.005). In the stenotic LAD zone, MBF did not change significantly. During adenosine and CGS-21680 infusion, stenosis/control zone MBF ratios were comparable (0.32±0.11 versus 0.27±0.10, P=NS), and transmural 201Tl and 99mTc-sestamibi count-activity ratios (0.48±0.11 and 0.51±0.09, respectively) were also comparable (P=NS). Myocardial scintigraphy uncovered perfusion defects in all dogs.

Conclusions—CGS-21680 elicits coronary vasodilation comparable to that of adenosine and produces profound heterogeneity of MBF and of 201Tl and 99mTc-sestamibi myocardial uptake, rendering it a promising agent for pharmacological myocardial perfusion imaging.


Key Words: adenosine • receptors • CGS-21680 • radioisotopes • imaging • coronary disease




This article has been cited by other articles:


Home page
CirculationHome page
D. K. Glover, M. Ruiz, K. Takehana, F. D. Petruzella, L. M. Riou, J. M. Rieger, T. L. Macdonald, D. D. Watson, J. Linden, and G. A. Beller
Pharmacological Stress Myocardial Perfusion Imaging With the Potent and Selective A2A Adenosine Receptor Agonists ATL193 and ATL146e Administered by Either Intravenous Infusion or Bolus Injection
Circulation, September 4, 2001; 104(10): 1181 - 1187.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Z. Gao, Z. Li, S. P. Baker, R. D. Lasley, S. Meyer, E. Elzein, V. Palle, J. A. Zablocki, B. Blackburn, and L. Belardinelli
Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 209 - 218.
[Abstract] [Full Text]